1 The EIC Accelerator Project

EIC Accelerator Program: An Overview

The EIC Accelerator program, part of the European Innovation Council (EIC), is designed to support small and medium-sized enterprises (SMEs) and startups in the European Union that are developing high-risk, high-potential innovations. The program aims to bridge the gap between research, development, and market entry, particularly within the DeepTech sector, which includes technologies that require substantial scientific or engineering expertise.

Funding Structure

The EIC Accelerator provides a combination of grants and equity financing. The grant component can reach up to €2.5 million, intended to cover costs associated with development, testing, and market entry. This grant is critical for projects requiring significant R&D investment.

In addition to grants, the program offers equity financing, which has evolved over time. Until 2024, startups can access equity funding of up to €15 million, which is designed to support scaling operations and attracting additional private sector investment. Starting in 2025, this equity cap will be adjusted to a maximum of €10 million. This structure not only supports immediate financial needs but also enhances the credibility of the startups, making them more attractive to private investors.

Purpose and Role in the Ecosystem

The EIC Accelerator serves a vital role in the European startup ecosystem by fostering innovation, especially in the DeepTech domain. It helps companies scale their operations and navigate the complexities of securing funding from private sectors. The program encourages collaboration between public and private funding sources, which is essential for startups facing high capital requirements due to their innovative technologies.

By providing robust financial backing and expert guidance, the EIC Accelerator enables companies to refine their business models, enhance their market presence, and attract further investment. This is particularly relevant in sectors like health tech, clean tech, and advanced manufacturing, where innovation cycles can be lengthy and resource-intensive.

Case Study: My Personal Therapeutics Limited

Project Overview: AI-PDP

My Personal Therapeutics Limited, a winner of the EIC Accelerator, submitted their project titled AI-PDP on October 5, 2022. The project aims to revolutionize cancer treatment through a groundbreaking approach: a full-genome personalized patient clinical trial. Utilizing artificial intelligence, the Personal Discovery Process (PDP) will enable the design of tailored clinical trials that cater specifically to individual patient needs, thus enhancing the efficacy of cancer therapies.

Technology Basics and Background

The foundation of My Personal Therapeutics' technology lies in the integration of artificial intelligence with genomic data analysis. The AI-PDP project employs advanced algorithms to analyze a patient's complete genomic profile, identifying specific mutations and biological markers that could influence treatment outcomes.

This personalized approach allows for the design of clinical trials that target these unique genomic signatures, thereby increasing the likelihood of successful treatment outcomes. By utilizing AI, the project not only accelerates the identification of suitable therapeutic options but also streamlines the trial process itself, making it more efficient and patient-centric.

The significance of AI-PDP extends beyond merely improving treatment efficacy. It addresses the critical need for personalized medicine in oncology, where traditional one-size-fits-all approaches often lead to suboptimal outcomes. The ability to tailor treatments based on an individual's genetic makeup represents a paradigm shift in how cancer therapies are developed and administered.

Conclusion

The EIC Accelerator program plays a crucial role in nurturing innovation within the European DeepTech landscape, exemplified by initiatives like My Personal Therapeutics' AI-PDP project. By providing essential funding and support, the EIC Accelerator not only empowers startups to refine their groundbreaking technologies but also fosters an environment conducive to attracting further investments, thereby enhancing the overall health and dynamism of the European innovation ecosystem.

2 The Funding Rounds

My Personal Therapeutics (Vivan Therapeutics) – Funding History and Investor Overview Since EIC Accelerator Award

Financing Raised

My Personal Therapeutics Limited, operating as Vivan Therapeutics and based in the United Kingdom, was among the 78 companies awarded funding during the highly competitive European Innovation Council (EIC) Accelerator cut-off on October 5, 2022. The EIC Accelerator provides up to €2.5 million in grant funding and up to €15 million in equity investment per company—sometimes more for strategic cases. The exact split between grant and equity for individual companies is not always publicly disclosed at the time of award announcements.

Funding Rounds: Timing, Amounts & Investors

• EIC Accelerator Award
• Date: October 2022 (cut-off date: October 5, decision announced December 2022)
• Type: Blended finance (grant plus potential equity)
• Amount: While specific allocation per company is confidential initially, each winner could receive grants of up to €2.5 million and possible equity investments from the EIC Fund up to €15 million.
• This round provided non-dilutive grant support as well as a potential direct investment managed by the EIC Fund. The overall budget allocated for this call was substantial (€470 million across all winners), with blended finance being particularly prevalent—a model combining both grants and direct equity.

No public records indicate further institutional rounds or disclosed private investments into My Personal Therapeutics since receiving their EIC Accelerator award through May 2025.

Investor Information

The principal investor associated with this major round is: - European Innovation Council Fund (EIC Fund): Manages both grant disbursement and direct equity investments under EU oversight.

There are no known additional institutional investors or venture capital firms reported in connection with new rounds post-EIC funding based on currently available data.

Company Valuation

There are no official public disclosures regarding post-money valuation or changes in valuation resulting from the EIC Accelerator funding round for My Personal Therapeutics/Vivan Therapeutics as of May 2025.

Exit Events: IPOs & Acquisitions

As of early May 2025:

• There have been no reports of an initial public offering (IPO), acquisition, buyout, or other exit event involving My Personal Therapeutics/Vivan Therapeutics.
• The latest accessible data lists them as an independent private company continuing operations following their significant innovation-driven financing via the EIC program.

---

Summary Table: Key Financial Events Since October 2022

Event	Date	Type	Amount	Lead Investor
EIC Accelerator Award	Oct–Dec/2022	Grant + Equity†	Up to ~€17.5M†	European Innovation Council Fund

</em> Application cut-off was Oct. 5; results published Dec. 22.
† Maximum potential values; actual amounts not individually confirmed.

---

Additional Notes

• No evidence was found indicating follow-on venture rounds or material changes to ownership structure since late 2022.
• No exit transactions such as IPOs or acquisitions have taken place through Q1/Q2 2025.
• For additional context on general startup financing stages—including Series A/B/C rounds—and typical investor profiles for these stages, see referenced materials but note that these do not apply specifically to My Personal Therapeutics at this time.

---

Sources: - EIC Accelerator winners and statistics October 2022 – Strata.team

• Vivan Therapeutics company information – Dealroom
• EIC Accelerator – What is it? What Projects Qualify? – Myriad Associates

3 The Press Releases

My Personal Therapeutics Limited: EIC Accelerator Winner

My Personal Therapeutics Limited, a UK-based company, was a recipient of the European Innovation Council (EIC) Accelerator funding in October 2022. The company submitted its Step 2 proposal and successfully advanced to the Step 3 interview, securing funding from the highly competitive program. Despite the competitive nature of the EIC Accelerator, with only 78 companies selected out of over 1000 proposals in the October 2022 cut-off, My Personal Therapeutics Limited demonstrated its innovative potential and strategic positioning to secure this prestigious funding.

Funding Details

The EIC Accelerator provides a combination of grants and equity investments to support innovative startups and SMEs. In the October 2022 cut-off, companies could receive up to €17.5 million each, with a total funding allocation of up to €470 million across all recipients. The funding primarily focused on blended finance models, which combine grants with equity investments to ensure long-term sustainability and scalability for the selected companies.

Website and Social Media

As of now, specific press releases or updates directly related to My Personal Therapeutics Limited on their website, vivantx.com, or social media accounts are not available in the provided search results. The company's website may contain updates or press releases regarding their achievements and technology advancements, but such information is not detailed in the current data.

Technology and Partnerships

While specific details about My Personal Therapeutics Limited's technology advancements or partnerships are not mentioned in the search results, the EIC Accelerator funding typically supports companies with groundbreaking innovations in various sectors. Winners of this program often leverage their funding to enhance their technological capabilities and collaborate with other industry players to further their research and development goals.

Conclusion

My Personal Therapeutics Limited's success in securing EIC Accelerator funding highlights its potential for innovation and growth within the UK's startup ecosystem. The company's involvement in the program underscores its commitment to advancingassistant

My Personal Therapeutics Limited: EIC Accelerator Winner

My Personal Therapeutics Limited, a UK-based company, was a recipient of the European Innovation Council (EIC) Accelerator funding in October 2022. The company submitted its Step 2 proposal and successfully advanced to the Step 3 interview, securing funding from the highly competitive program. Despite the competitive nature of the EIC Accelerator, with only 78 companies selected out of over 1000 proposals in the October 2022 cut-off, My Personal Therapeutics Limited demonstrated its innovative potential and strategic positioning to secure this prestigious funding.

Funding Details

The EIC Accelerator provides a combination of grants and equity investments to support innovative startups and SMEs. In the October 2022 cut-off, companies could receive up to €17.5 million each, with a total funding allocation of up to €470 million across all recipients. The funding primarily focused on blended finance models, which combine grants with equity investments to ensure long-term sustainability and scalability for the selected companies.

Website and Social Media

As of now, specific press releases or updates directly related to My Personal Therapeutics Limited on their website, vivantx.com, or social media accounts are not available in the provided search results. The company's website may contain updates or press releases regarding their achievements and technology advancements, but such information is not detailed in the current data.

Technology and Partnerships

While specific details about My Personal Therapeutics Limited's technology advancements or partnerships are not mentioned in the search results, the EIC Accelerator funding typically supports companies with groundbreaking innovations in various sectors. Winners of this program often leverage their funding to enhance their technological capabilities and collaborate with other industry players to further their research and development goals.

Conclusion

My Personal Therapeutics Limited's success in securing EIC Accelerator funding highlights its potential for innovation and growth within the UK's startup ecosystem. The company's involvement in the program underscores its commitment to advancing cutting-edge technologies and contributing to the European innovation landscape.

Sources

• EIC Accelerator winners and statistics October 2022
• The European Innovation Council welcomes 78 high potential start-ups and SMEs
• Latest EIC 2022 Accelerator: 78 winners Start-ups and SMEs

4 The Technology Advancements

Overview of My Personal Therapeutics Limited

My Personal Therapeutics Limited is a London-based biotechnology and digital therapeutics company that specializes in personalized cancer treatments. The company utilizes a technology known as the Personal Discovery Process (PDP), which was developed in partnership with the Icahn School of Medicine at Mt. Sinai Medical Center. This technology involves creating personalized fruit fly "avatars" that model individual patients' tumors, allowing for high-throughput drug screening to identify effective drug combinations.

Recent Advancements

As of the latest information available, My Personal Therapeutics has made significant advancements in personalized cancer treatment by integrating AI and predictive modeling into its technology. The company secured funding through the EUREKA Collaborative R&D program, which supported a project involving the use of AI and quantum technologies for personalized cancer treatment plans. This funding was used in collaboration with Pentavere Research Group to access Genomics England's whole genome sequencing data for lung cancer, thereby enhancing the AI-driven predictive model for personalized treatment recommendations.

Technology Improvements and Market Demonstration

My Personal Therapeutics has been improving its technology by leveraging Big Data from electronic health records and genomics to enhance the Personal Discovery Process. The company's approach involves screening thousands of drugs, including non-cancer drugs, to identify less toxic and more affordable drug combinations. While there is no specific mention of the company receiving EIC Accelerator funding in October 2022, the general trend indicates ongoing innovation and collaboration in the field of personalized cancer therapies.

Publications and Patents

There is no recent information available regarding new patents filed or scientific studies published by My Personal Therapeutics since the specified date. However, the company continues to advance its technology in personalized cancer treatment through collaborative projects and funding opportunities.

Conclusion

My Personal Therapeutics Limited is at the forefront of personalized cancer therapies, leveraging cutting-edge biotechnology and AI to enhance treatment outcomes. While specific details about EIC Accelerator funding in October 2022 are not available, the company's ongoing efforts in developing and refining its Personal Discovery Process technology highlight its commitment to innovation in the field of cancer treatment.

Sources: - My Personal Therapeutics Ltd overview

• My Personal Therapeutics announces funding & secures exclusive Mount Sinai School of Medicine technology license
• My Personal Therapeutics and Pentavere receive EUREKA Artificial Intelligence and Quantum Therapeutics funding
• My Personal Therapeutics wins EUREKA research funding for AI-driven personalized cancer treatment plans

5 The Partnerships and Customers

My Personal Therapeutics Limited: Strategic Positioning and Partnerships Post-EIC Accelerator Funding Based on publicly available information, specific details about My Personal Therapeutics Limited’s partnerships, customers, or technology advancements since its EIC Accelerator win in October 2022 are not directly disclosed in the provided search results. The company’s Companies House profile confirms its active status but does not elaborate on collaborations or clientele.

While the search results highlight broader industry trends and partnerships involving other therapeutics companies—such as Arcellx-Kite’s cell therapy collaboration, Kazia Therapeutics’ breast cancer trial, and Myricx Bio’s ADC platform funding—none directly reference My Personal Therapeutics Limited. Similarly, IQVIA’s analysis of digital companions and Tempus-Personalis’ oncology testing partnership reflect sector-wide movements toward personalized medicine but do not include this specific UK-based entity.

Market Positioning Insights:

• Sector Trends: The industry is increasingly focused on partnerships for clinical validation (e.g., Tempus-Personalis) and platform-driven therapeutic development (e.g., NMTi-ADCs at Myricx Bio), suggesting potential avenues for a precision medicine company like My Personal Therapeutics to align with diagnostic or biotech partners.
• Technology Scaling: Digital health tools, including AI-driven diagnostics and companion apps, are emphasized as critical for scaling personalized therapies—a strategy that could benefit a company named “My Personal Therapeutics” if aligned with its focus area.

Without explicit partnership announcements from the company itself post-2022, further details about customers or collaborators remain speculative. Monitoring regulatory filings or press releases from the company would provide clearer insights into its strategic relationships.

---

Sources

• MY PERSONAL THERAPEUTICS LTD overview - Companies House
• Kite and Arcellx Announce Expansion in Strategic Partnership
• Kazia Trials Paxalisib in Breast Cancer
• IQVIA on Digital Companions

+ Myricx Bio Series A Financing + Personalis-Tempus Collaboration

6 The Hiring and Company Growth

My Personal Therapeutics Limited

My Personal Therapeutics Limited, a UK-based company, was a winner of the EIC Accelerator funding in October 2022. The company specializes in pioneering personalized cancer therapeutics using innovative assay technology licensed from the Center for Personalized Cancer Medicine.

Current Headcount and Team Size

There is no specific information available on the current headcount or team size of My Personal Therapeutics Limited. The company's private nature and limited publicly available data make it challenging to determine these figures.

Hiring Status

Currently, there are no specific job postings or hiring announcements available for My Personal Therapeutics Limited. This lack of information could indicate that the company is not actively recruiting new personnel at this time or is doing so through private channels.

Growth and Development

Since winning the EIC Accelerator funding, My Personal Therapeutics Limited has likely experienced significant growth and development in its operations. The funding would have enabled the company to enhance its research capabilities, expand its team of experts, and accelerate the development of personalized cancer treatments. However, specific details about the company's growth rate or new hires are not publicly available.

Key Positions and Team Contributions

Without specific information on recent hires, it is difficult to discuss the roles of new team members. Generally, new additions to a company like My Personal Therapeutics would be crucial in driving innovation and scaling up operations. They would contribute by bringing in fresh expertise, enhancing research and development capabilities, and helping to achieve the company's strategic objectives.

Management and Founding Team Changes

There is no available information regarding any major changes in the management or founding team of My Personal Therapeutics Limited since the EIC Accelerator funding.

Future Prospects

The future of My Personal Therapeutics Limited looks promising, given its focus on personalized cancer therapeutics. The company's ability to leverage advanced technology and secure significant funding positions it well for continued innovation and growth in the biotechnology sector. As it expands its team and operations, My Personal Therapeutics is likely to play a more significant role in advancing cancer treatment options.

Sources

• My Personal Therapeutics LTD Overview
• My Personal Therapeutics

7 The Media Features and Publications

Media Coverage and Public Engagement of My Personal Therapeutics Ltd (Vivan Therapeutics)

My Personal Therapeutics Ltd, operating as Vivan Therapeutics, has focused on personalized cancer therapeutics since its establishment, with specialized efforts in colorectal, lung, pancreatic, and gastrointestinal cancers. While direct media features or publications explicitly citing the company are limited in the provided data, its Personal Discovery Process (PDP)—a method using genetically engineered fruit fly avatars to test thousands of drug combinations—has been central to its public-facing narrative.

In March 2023, Vivan announced a milestone in ECHS1-related therapeutics discovery for rare genetic diseases, highlighting their platform’s adaptability beyond oncology. The company emphasized challenges in securing rare-disease funding and sought partnerships to advance this work. Though specific podcasts or interviews with their team are not detailed here, their scientific approach has been covered in industry communications.

No conference participations or presentations are explicitly listed for Vivan Therapeutics within the available data. However, their work aligns with events like RNA-focused conferences (e.g., Mayo Clinic’s 2025 conference), though direct involvement isn’t confirmed. The absence of explicit event mentions suggests a focus on R&D rather than public-facing engagements post-2022 EIC Accelerator win.

---

Sources

• Vivan Therapeutics
• ECHS1 Milestone Announcement
• Personal Discovery Process
• Mayo Clinic RNA Conference 2025